Abstract
Recently, molecular-biological analyses of the mechanisms of cancer development have created new anticancer agents, molecular-targeted agents. Among them, the humanized anti-HER 2 monoclonal antibody, trastuzumab (Herceptin), has been available for clinical use in metastatic breast cancer in Japan since June, 2001. Now, it has become one of the key drugs for metastatic breast cancer. Recently, large-scale randomized trials revealed its usefulness in the adjuvant setting of postoperative breast cancer. Furthermore, a new anti-angiogenic agent, bevacizumab, showed significant survival benefits with paclitaxel in metastatic breast cancer. This paper reviews the details of these molecular-targeted agents are reviewed in clinical studies.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Breast Neoplasms / chemistry
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Clinical Trials as Topic
-
Docetaxel
-
Drug Administration Schedule
-
Drug Delivery Systems
-
Female
-
Humans
-
Indoles / administration & dosage
-
Lapatinib
-
Middle Aged
-
Paclitaxel / administration & dosage
-
Pyrroles / administration & dosage
-
Quinazolines / administration & dosage
-
Randomized Controlled Trials as Topic
-
Receptor, ErbB-2 / analysis
-
Sunitinib
-
Taxoids / administration & dosage
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Indoles
-
Pyrroles
-
Quinazolines
-
Taxoids
-
Lapatinib
-
Docetaxel
-
Bevacizumab
-
Receptor, ErbB-2
-
Trastuzumab
-
Paclitaxel
-
Sunitinib